Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells

Proteasome inhibition is an attractive approach for anticancer therapy. Doxorubicin (DOX) is widely used for treatment in a number of cancers including breast cancer; however, the development of DOX resistance largely limits its clinical application. One of the possible mechanisms of DOX-resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yonghua, Yu, Yang, Wang, Zhenyu, Wang, Hao, Bieerkehazhi, Shayahati, Zhao, Yanling, Suzuk, Lale, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342008/
https://www.ncbi.nlm.nih.gov/pubmed/27655642
http://dx.doi.org/10.18632/oncotarget.12048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342008/
https://www.ncbi.nlm.nih.gov/pubmed/27655642
http://dx.doi.org/10.18632/oncotarget.12048

Ejemplares similares